RecruitingNCT07527624

Evaluation of Socio-professional Inclusion for Young Adults Aged 15-25 Living With a Rare Genetic Disability


Sponsor

Imagine Institute

Enrollment

300 participants

Start Date

Jan 8, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Rare diseases are often synonymous with difficulties for sufferers, whether physical, mental or social. Patients suffering from rare diseases face specific problems, such as the long wait for a diagnosis, the geographical distance between the rare disease reference center and home, and the isolation created by this very disabling disease... Children suffering from rare genetic diseases have difficulty accessing higher education, but above all in finding an internship or work-study placement, due to the rarity of their disability. The aim of this study, entitled "Imagine La Suite", is to assess the difficulties encountered by young people with rare genetic diseases and disabilities in their search for vocational and university training or employment.


Eligibility

Min Age: 15 YearsMax Age: 25 Years

Inclusion Criteria7

  • Current age 15-25 years born between 1997 and 2007
  • Rare genetic disease confirmed by a genetic test, originating in childhood and followed at Necker in the networks of the following disease reference centers:
  • epilepsy without deficiency ;
  • genodermatosis ;
  • constitutional bone diseases ;
  • craniofacial malformations;
  • deafness;

Exclusion Criteria3

  • Patient or parent's opposition to study participation
  • Patient with intellectual disability (IQ < 70)
  • Patients with pathologies involving intellectual disability and patients with a clinical sign of intellectual disability.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERsurvey

Patients take part in a survey, completing a form in less than 30 minutes


Locations(1)

Imagine Clinical Research

Paris, Île-de-France Region, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07527624


Related Trials